Nilotinib (AMN-107)

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nilotinib (AMN-107) Chemical Structure

Nilotinib (AMN-107) Chemical Structure
Molecular Weight: 529.52

Validation & Quality Control

Customer Product Validation(5)

Quality Control & MSDS

Related Compound Libraries

Bcr-Abl Inhibitors with Unique Features

  • Pan Bcr-Abl Inhibitor

    Imatinib Mesylate (STI571) Multi-target inhibitor of v-Abl, c-Kit and PDGFRIC50=0.6 μM/0.1 μM/0.1 μM.

  • Most Potent Bcr-Abl Inhibitor

    GZD824 Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.

  • FDA-approved Bcr-Abl Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Bcr-Abl Inhibitor

    GZD824 Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Product Information

  • Compare Bcr-Abl Inhibitors
    Compare Bcr-Abl Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Targets Bcr-Abl [1]
(Murine myeloid progenitor cells)
IC50 <30 nM
In vitro Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellNGP0b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7oTWM2OD1yLkCwNFE1PCEQvF2=NITTc|BUSU6JRWK=
KU812M1zjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHlR|hKSzVyPUCuNFAzPDhizszNMnTPV2FPT0WU
EM-2MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTBwMEC0NUDPxE1?NILpUmZUSU6JRWK=
LAMA-84M{DUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTwTWM2OD1yLkCwOFkh|ryPMUDTRW5ITVJ?
MEG-01MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jQPGlEPTB;MD6wNFgzQCEQvF2=NGTnZpBUSU6JRWK=
BV-173NWH1T45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTBwMEGwPFkh|ryPMnLuV2FPT0WU
KASUMI-1NWe2bFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzmTWM2OD1yLkCyOFE{KM7:TR?=NHuxO4FUSU6JRWK=
NB7M2rEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVuydFZtUUN3ME2wMlE{PDN7IN88US=>NVT4NWl5W0GQR1XS
BHT-101MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7W[nRKSzVyPUCuOlQzPjNizszNM4fmOnNCVkeHUh?=
CGTH-W-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjzcnpHUUN3ME2wMlY1QDdizszNNUT6XmRxW0GQR1XS
HMV-IIM2jCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fyemlEPTB;MD63OFg4PCEQvF2=M3LZOHNCVkeHUh?=
NKM-1NEPjeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHn1N|dKSzVyPUCuPVAyPSEQvF2=MoHvV2FPT0WU
LB2241-RCCNWHjO4NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojDTWM2OD1zLkCyNlI5KM7:TR?=MV7TRW5ITVJ?
NCI-H1703MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4KyXmlEPTB;MT6xPFg4KM7:TR?=MXXTRW5ITVJ?
BE-13MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfEfWdZUUN3ME2xMlI4PDF4IN88US=>NFezcGZUSU6JRWK=
ACNM1XWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\hTWM2OD1zLkW1NFc4KM7:TR?=NXjYTJBTW0GQR1XS
A204Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTFwNUeyNFUh|ryPM125XHNCVkeHUh?=
HOP-62MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjITWM2OD1zLkiyNFc4KM7:TR?=NYDocpA1W0GQR1XS
H9NYXNOG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrJPHUxUUN3ME2yMlc{Pzl|IN88US=>NEf5V2JUSU6JRWK=
HCC1806MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJwN{SzNlch|ryPMlL4V2FPT0WU
NOS-1M1f1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XXRmlEPTB;Mj64O|ExOiEQvF2=MWPTRW5ITVJ?
RS4-11NWX2fG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTJwOUC2NlMh|ryPMWnTRW5ITVJ?
JARNHrCWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfITWM2OD1{LkmyNFg1KM7:TR?=NHXOPYhUSU6JRWK=
T98GNELtS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnWdZpKSzVyPUOuNFE{OTNizszNMl\GV2FPT0WU
NCI-SNU-1MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrIRYpKSzVyPUOuOFAxQTJizszNM2nEd3NCVkeHUh?=
SK-MEL-1NEfwXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfZVYM3UUN3ME2zMlQ{ODJ7IN88US=>NVLGR3NtW0GQR1XS
L-363M4LZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTNwNkGxNFch|ryPMXLTRW5ITVJ?
SW982MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1mxfGlEPTB;Mz62OFE3QSEQvF2=NX\CSINQW0GQR1XS
HT-1080NVzyc5k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTNwOUG3O|Uh|ryPM{XnOnNCVkeHUh?=
G-402M3;m[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknjTWM2OD12LkOxNlA{KM7:TR?=NIHXWo1USU6JRWK=
HOSMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PFVGlEPTB;ND64NFI5OiEQvF2=NEjH[YZUSU6JRWK=
SK-NEP-1M1GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TEPGlEPTB;ND64N|E6OSEQvF2=M{KzU3NCVkeHUh?=
HAL-01NHHLOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVmwfoFvUUN3ME20Mlg5OjR{IN88US=>NFTtNZRUSU6JRWK=
SBC-1M4DIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\VTWM2OD12LkmwPVA4KM7:TR?=MmLwV2FPT0WU
CTV-1NGTvN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjnRpZKSzVyPUWuOFg6OzhizszNMUnTRW5ITVJ?
LCLC-103HMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\SZmlEPTB;NT63O|Q4OSEQvF2=M3\lcXNCVkeHUh?=
RVH-421NVXnfHFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPQZZRUUUN3ME21Mlc4PTN4IN88US=>MV;TRW5ITVJ?
K-562MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPv[Y5KSzVyPUWuPVA{PiEQvF2=NVLyTW95W0GQR1XS
CAL-33NUDZbWNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnITWM2OD14LkOxN|U6KM7:TR?=M1;GUnNCVkeHUh?=
MDA-MB-361M1Ww[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjYV2pKSzVyPU[uN|M3QTlizszNMnS4V2FPT0WU
IGROV-1M4Dod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4C3eWlEPTB;Nj60O|E6OSEQvF2=NW\QWXJ6W0GQR1XS
NYM{LvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\ve|RtUUN3ME22MlU{PTl7IN88US=>MkHEV2FPT0WU
Ramos-2G6-4C10M4nUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTZwNk[5N|Eh|ryPM{XEOnNCVkeHUh?=
HuO9NVO4[oVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTZwN{O5OlQh|ryPMXvTRW5ITVJ?
MS-1NWTtfVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LTV2lEPTB;Nz6xNVk2OyEQvF2=NWmx[llwW0GQR1XS
RPMI-8226M{PO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTdwMkiyPFch|ryPMnq3V2FPT0WU
HDLM-2NGLjTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf3RXZKSzVyPUeuOFAyPDlizszNM{DTRXNCVkeHUh?=
D-566MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTdwNEexOVUh|ryPNIPGfG5USU6JRWK=
SK-MEL-24MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XnTGlEPTB;Nz62N|M6OiEQvF2=MX7TRW5ITVJ?
COLO-679MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTdwOUi2O|Eh|ryPM{i4PHNCVkeHUh?=
EW-13MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRThwM{KwOVQh|ryPM4PGbnNCVkeHUh?=
A388MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;NTWM2OD16LkO4OFgyKM7:TR?=M2Pj[nNCVkeHUh?=
UM-UC-3NWH3[2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXEdYpYUUN3ME24MlQ{QTV4IN88US=>NVTZPWZkW0GQR1XS
NUGC-3MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRThwNUO1PFIh|ryPNUXWWVdEW0GQR1XS
COLO-668NYPHWXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRThwNUm0PVEh|ryPM4\YeXNCVkeHUh?=
MOLT-4NH\hbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PzbmlEPTB;OD62NlM2OyEQvF2=MnntV2FPT0WU
D-423MGNHuxZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfldHJvUUN3ME24Mlg{PzV4IN88US=>MoTXV2FPT0WU
CTB-1Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PvOWlEPTB;OD64O|EzQCEQvF2=NHznN5RUSU6JRWK=
BCPAPNVXHSHN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPQPVFKSzVyPUmuNFI2PjJizszNM1\rTnNCVkeHUh?=
GCTMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYizUHd5UUN3ME25MlA6QDNzIN88US=>MV;TRW5ITVJ?
ACHNNHP4V|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTlwMkO2N|Ih|ryPNUnGSplwW0GQR1XS
KYSE-520M4XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHk[pFKSzVyPUmuN|M1QDJizszNMWnTRW5ITVJ?
LB771-HNCMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXrfmZLUUN3ME25Mlc3PDl5IN88US=>MV3TRW5ITVJ?
MLMAMn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjwU5ljUUN3ME2xNE4xOTN{IN88US=>NEG3bYtUSU6JRWK=
HEC-1MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHrW4ltUUN3ME2xNE4zQDB2IN88US=>M2LhTHNCVkeHUh?=
HL-60NEfzPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPjUoQ1UUN3ME2xNE43QDV|IN88US=>NUDxWIZDW0GQR1XS
A101DMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3njWGlEPTB;MUCuPFkzOyEQvF2=M4rGUXNCVkeHUh?=
A2058M{jpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:we4VsUUN3ME2xNE46OjR3IN88US=>MVfTRW5ITVJ?
KARPAS-45MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2q5ZmlEPTB;MUGuNFY{PSEQvF2=M1m2WHNCVkeHUh?=
697NFPmeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTFzLkKxNFEh|ryPMoexV2FPT0WU
NCI-N87NXfBc5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXTTWM2OD1zMT63O|MyKM7:TR?=M2O5UnNCVkeHUh?=
DSH1MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nyWmlEPTB;MUGuO|k2OyEQvF2=NETLWphUSU6JRWK=
HLEM1nq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTFzLki4N|kh|ryPMV3TRW5ITVJ?
NCI-H720MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TRTWlEPTB;MUKuOlgxOSEQvF2=MX;TRW5ITVJ?
EW-3MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzkTWM2OD1zMj65N|A4KM7:TR?=NGPOOZJUSU6JRWK=
AGSM1\yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\HeXVKSzVyPUGzMlA{PTFizszNNV3xZVdPW0GQR1XS
ES5M1L5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDMTWM2OD1zMz6wOVEzKM7:TR?=NYHhUJVlW0GQR1XS
DBMl21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTF|LkOyOVYh|ryPNH7QeY5USU6JRWK=
A4-FukMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3LTWM2OD1zMz60NVAzKM7:TR?=NYXLTXl3W0GQR1XS
A427NGj3ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LHdWlEPTB;MUOuOFk4OiEQvF2=MX3TRW5ITVJ?
MN-60M3TkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTF|LkW4OFMh|ryPM4\oeHNCVkeHUh?=
HCC2218NWPPOmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\JW2lEPTB;MUOuOVg2PiEQvF2=NILGfZBUSU6JRWK=
MV-4-11M4TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF|LkixN|ch|ryPMlTPV2FPT0WU
GI-1NXewbnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTF2LkGxPFQh|ryPM{TmXnNCVkeHUh?=
JVM-3MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWqxO3FMUUN3ME2xOE4zPjV4IN88US=>M4LMc3NCVkeHUh?=
NCI-H2029MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;XOYRKSzVyPUG0MlI4OjdizszNM{nQPHNCVkeHUh?=
TE-12M{D4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnFfYh5UUN3ME2xOE43ODR4IN88US=>M3jTcnNCVkeHUh?=
WM-115NFLPfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP2TWM2OD1zNT61Olg{KM7:TR?=M{\0NnNCVkeHUh?=
BB65-RCCNUnocGFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTF4LkCyOFEh|ryPMV\TRW5ITVJ?
NCI-H1693MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF4LkO4NFIh|ryPMXXTRW5ITVJ?
KARPAS-299NUK5S4Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPPRnY4UUN3ME2xOk43OjB|IN88US=>MW\TRW5ITVJ?
UACC-257NFe2elBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqxTWM2OD1zNz6wOVgzKM7:TR?=NGjLRZBUSU6JRWK=
RKOMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jF[mlEPTB;MUeuOlQ{OyEQvF2=M3rhfXNCVkeHUh?=
HT-29M4nOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFW0[FlKSzVyPUG3Mlc5QDlizszNMXnTRW5ITVJ?
ES7MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTF6LkGxNlIh|ryPMWnTRW5ITVJ?
DELNH3OU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LaWGlEPTB;MUiuN|E4OiEQvF2=MWHTRW5ITVJ?
BT-549M{eyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF6LkSwPVIh|ryPMlX0V2FPT0WU
NCI-H1755Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLJOnNKSzVyPUG4MlU4OjNizszNNXqzNZp6W0GQR1XS
HCE-TNUXTOJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPwTWM2OD1zOD64N|QyKM7:TR?=NHzJZ4lUSU6JRWK=
LU-139NUDYc|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHCdW1KSzVyPUG5MlA1PThizszNNFXvc3lUSU6JRWK=
ECC10MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X0XmlEPTB;MUmuNlQ4PSEQvF2=NXvhOIhFW0GQR1XS
769-PNV3TV4c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPsOJNZUUN3ME2xPU43OzN3IN88US=>MXfTRW5ITVJ?
BALL-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF7Lk[3O|Uh|ryPMWrTRW5ITVJ?
LXF-289M1jHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHrTWM2OD1zOT64PVc6KM7:TR?=NUnRUI13W0GQR1XS
TYK-nuNUjPXHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTF7LkmzNVUh|ryPMX\TRW5ITVJ?
NCI-H630NILXUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfkTWM2OD1zOT65N|c5KM7:TR?=MUfTRW5ITVJ?
EW-18NHLnTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHP3T2tKSzVyPUKwMlM5ODJizszNMUfTRW5ITVJ?
KYSE-150NG\yd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jDO2lEPTB;MkCuO|A1PyEQvF2=MoDSV2FPT0WU
LOXIMVIM4fXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXQTWM2OD1{MD63OVg3KM7:TR?=MUPTRW5ITVJ?
HuP-T3M1nJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O0c2lEPTB;MkGuNFg2OiEQvF2=MmLpV2FPT0WU
MFE-280MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[4dnNKSzVyPUKxMlU3PzlizszNNX7kUG1sW0GQR1XS
SK-OV-3M3OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\zTWM2OD1{MT64OFA5KM7:TR?=M3zQcHNCVkeHUh?=
QIMR-WILM4njRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJ{LkC0O|gh|ryPM4ruVXNCVkeHUh?=
NCI-H69Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnj5TWM2OD1{Mj60Nlk6KM7:TR?=NVP0OVREW0GQR1XS
TE-5NVTXbpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTJ{LkS5OlUh|ryPNIDvZWJUSU6JRWK=
NCI-H1993Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXTTWM2OD1{Mj60PVcyKM7:TR?=NVfqbHFFW0GQR1XS
NCI-H1092MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PjUWlEPTB;MkOuNlg1OyEQvF2=NWP4ZVNUW0GQR1XS
RH-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPQTWM2OD1{Mz61N|U4KM7:TR?=M3TJ[HNCVkeHUh?=
DBTRG-05MGMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLCOJhOUUN3ME2yN{45PDd{IN88US=>NEn6XJFUSU6JRWK=
Mo-TMnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJ|Lkmg{txOMl2yV2FPT0WU
HD-MY-ZMly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPnTWM2OD1{ND6yN|YzKM7:TR?=Mo\PV2FPT0WU
NCI-H2342NWj6b5FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPCOJFKSzVyPUK0MlY4PjdizszNM4KzRXNCVkeHUh?=
C32MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTD[3pCUUN3ME2yOE46PTd4IN88US=>MnjjV2FPT0WU
HTC-C3M1vlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr6TWM2OD1{NT6zOVc4KM7:TR?=MlvmV2FPT0WU
NCI-H358M4fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJ3LkO5OFMh|ryPMmGzV2FPT0WU
CAL-85-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDZTHhKSzVyPUK1MlQ2PzdizszNNHTHT3lUSU6JRWK=
HT-1197MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37Ud2lEPTB;MkWuOVMyQSEQvF2=NFnEVZJUSU6JRWK=
A172NGTJ[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[xcJpHUUN3ME2yOU44OTN4IN88US=>MX\TRW5ITVJ?
SW1573M{XJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvETWM2OD1{NT63O|g2KM7:TR?=Mn7tV2FPT0WU
EW-24MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTwUVlSUUN3ME2yOU46PjJizszNMnSxV2FPT0WU
SK-MEL-2NITXcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvFTWM2OD1{Nj6wN|EzKM7:TR?=M1Hnc3NCVkeHUh?=
LU-65NYLUfIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnKTWM2OD1{Nj6wOFUzKM7:TR?=M1rscHNCVkeHUh?=
KMOE-2M2nQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJ4LkC5NVUh|ryPM{f0d3NCVkeHUh?=
H-EMC-SSNE\Rd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPrfpc4UUN3ME2yOk41OTF2IN88US=>MX7TRW5ITVJ?
H4NYTRV3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\QN2NpUUN3ME2yOk41OjR|IN88US=>NFmyRXBUSU6JRWK=
DU-4475NWmx[XpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkOxTWM2OD1{Nz6xPFczKM7:TR?=M13WeXNCVkeHUh?=
HCT-116MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\qbWlEPTB;MkeuOFM1QSEQvF2=NF[yZlBUSU6JRWK=
MSTO-211HMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXsc|BKSzVyPUK3MlYzPTVizszNNFrGbnlUSU6JRWK=
NCI-H292MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJ5Lkm2NVch|ryPMWDTRW5ITVJ?
NCI-H446MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPlc2RxUUN3ME2yPE4zOTB3IN88US=>NFjoUZRUSU6JRWK=
NCI-H2009M4HpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTJ7LkG0N|Eh|ryPNUfyepptW0GQR1XS
MHH-ES-1NF7HRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVW4bmhQUUN3ME2yPU4{Pjh3IN88US=>NVPPZYlRW0GQR1XS
TI-73MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJ7LkSwNFEh|ryPMV\TRW5ITVJ?
NCI-H2228MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTJ7LkS1PEDPxE1?NVjhfZJKW0GQR1XS
MHH-PREB-1NGfPenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInXT3hKSzVyPUK5MlU2ODVizszNMm\UV2FPT0WU
ChaGo-K-1M{LtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDEPIRFUUN3ME2yPU43ODl5IN88US=>M1Tj[3NCVkeHUh?=
KY821NETlNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ7Lk[0N|Mh|ryPMkXrV2FPT0WU
NCI-H209Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml[yTWM2OD1{OT64N|Y3KM7:TR?=NGKzcWpUSU6JRWK=
NBsusSRMnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\wTGlEPTB;MkmuPVkxPCEQvF2=M4HJR3NCVkeHUh?=
NCI-H1304NHntUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrMTWM2OD1|MD61O|E3KM7:TR?=NV;YbJFPW0GQR1XS
NB14M3PXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4T1OmlEPTB;M{GuNFQ1PiEQvF2=MVvTRW5ITVJ?
HCC1419NX\NfJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XpSWlEPTB;M{GuNlQh|ryPNIHs[ohUSU6JRWK=
KG-1MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULZd|FwUUN3ME2zNU44PDJ7IN88US=>NEnBc41USU6JRWK=
A2780MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTNzLkizOVgh|ryPMX3TRW5ITVJ?
NCI-H28NXfEUGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\0OmlEPTB;M{GuPVg3OSEQvF2=MmXpV2FPT0WU
C2BBe1MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nnZmlEPTB;M{KuNlY{PCEQvF2=MVXTRW5ITVJ?
VA-ES-BJMni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTN{LkOxJO69VQ>?NVTWO|A3W0GQR1XS
SBC-5NXnmbJdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DUNmlEPTB;M{KuPFUyOSEQvF2=NX;vdFdOW0GQR1XS
OVCAR-4NXjrZ2NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTN|LkS4OFgh|ryPM4fiUnNCVkeHUh?=
COR-L88M3ix[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjrWFNPUUN3ME2zOE4xPzRzIN88US=>MW\TRW5ITVJ?
SW954MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnmWopTUUN3ME2zOE4xPzV{IN88US=>NYfhSJpkW0GQR1XS
COLO-684MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvhOZo{UUN3ME2zOE4{PDB2IN88US=>NIezeZZUSU6JRWK=
HCC70MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFX3So5KSzVyPUO0Mlk2OTRizszNMVLTRW5ITVJ?
NCI-H1770MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTN2Lkm2NUDPxE1?NIXacXlUSU6JRWK=
NCI-H1666M4DEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTN3LkiyOVMh|ryPNVHBNINTW0GQR1XS
YH-13NELTcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfKd2VKSzVyPUO1MlkzKM7:TR?=MUnTRW5ITVJ?
DJM-1NHPBZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHMT49EUUN3ME2zOk45ODR7IN88US=>NFfCWYtUSU6JRWK=
KNS-62MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rwNGlEPTB;M{[uPVQ{QCEQvF2=NV7yVWFMW0GQR1XS
SK-MEL-30MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljrTWM2OD1|Nz64O|M4KM7:TR?=M3jCfnNCVkeHUh?=
SJRH30MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;lfWlEPTB;M{iuO|M1OSEQvF2=NHL6PIZUSU6JRWK=
GP5dNIP1PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\vT3pKSzVyPUO4Mlg3PTNizszNNVL5eoR1W0GQR1XS
SW1116M335TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDBTWM2OD1|OT6yPFA2KM7:TR?=MonMV2FPT0WU
COLO-800NUfYfmlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIexfJRKSzVyPUO5MlM3OzhizszNMVLTRW5ITVJ?
RDM1XEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;oV2lEPTB;M{muOVI2QCEQvF2=M3;ib3NCVkeHUh?=
NCI-SNU-5NWXhSWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\iNmhlUUN3ME2zPU43QTF4IN88US=>MXnTRW5ITVJ?
HuO-3N1MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1X1R2lEPTB;NECuNVA5KM7:TR?=NV32XZRsW0GQR1XS
SK-UT-1NEDqNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTRyLkW2O|Qh|ryPMnT2V2FPT0WU
SK-MEL-3Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3CXXAxUUN3ME20NE42QTN{IN88US=>MV7TRW5ITVJ?
SK-MEL-28MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHY[|FzUUN3ME20NE43PDN3IN88US=>M2LQeXNCVkeHUh?=
SCC-4M3u1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\ETWM2OD12MT6yNVM4KM7:TR?=MY\TRW5ITVJ?
no-11NWLXd5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3xd45KSzVyPUSxMlc{PTRizszNMX7TRW5ITVJ?
HT-144NWLoXnpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTR{LkC1Olch|ryPNYC0T3lqW0GQR1XS
MFM-223M2rjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPs[XFKSzVyPUSyMlQxOiEQvF2=NV\MWlBFW0GQR1XS
ONS-76MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTR{LkiwNVgh|ryPMk\5V2FPT0WU
ES8NX7lcGZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnITWM2OD12Mz6zOlk5KM7:TR?=M3PXZnNCVkeHUh?=
T-24NHO2cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXqxbnhXUUN3ME20N{41OzZ7IN88US=>NVLtV2ZLW0GQR1XS
GAMGNEO5OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Syc2lEPTB;NEOuOFUyPyEQvF2=MnvsV2FPT0WU
LU-135NYjyOYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnGTWM2OD12ND6wPVI{KM7:TR?=NVu0OWIyW0GQR1XS
HCC1187MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLmS2JKSzVyPUS0MlgzPjJizszNMmrYV2FPT0WU
TE-1M3nrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILtWYZKSzVyPUS1MlE3PTRizszNNITsd5ZUSU6JRWK=
J-RT3-T3-5NW\FdZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfhTW9XUUN3ME20OU41OzF3IN88US=>M1rUW3NCVkeHUh?=
GI-ME-NMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnzTWM2OD12NT64PVUzKM7:TR?=MofRV2FPT0WU
D-392MGNH2xXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LLeGlEPTB;NEWuPVI2PiEQvF2=MX7TRW5ITVJ?
KALS-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlyxTWM2OD12Nj63NlU4KM7:TR?=MkHSV2FPT0WU
MMAC-SFM2q0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3P6bGlEPTB;NE[uPVk2OiEQvF2=NIjj[nhUSU6JRWK=
HSC-3NGD1O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTR5LkO2NFgh|ryPMkOxV2FPT0WU
KM-H2M{D4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M36xb2lEPTB;NEeuOlAxPyEQvF2=NYH5SlJCW0GQR1XS
LoVoMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfVTWM2OD12OD6xNFAzKM7:TR?=NH;z[3VUSU6JRWK=
NCI-H510ANFO2OVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{K5WmlEPTB;NEiuNVg4OSEQvF2=MVvTRW5ITVJ?
EW-11MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qwWmlEPTB;NEiuNlM1QCEQvF2=NITlXnJUSU6JRWK=
HCC2998NYjvV4ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfjdnBKSzVyPUS4MlYzOzZizszNMVXTRW5ITVJ?
J82MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTR6LkeyOFIh|ryPMnPOV2FPT0WU
ML-2Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTR7LkS2NFUh|ryPMlLhV2FPT0WU
NCI-H2030MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVy5Z2NmUUN3ME20PU44OTF5IN88US=>MXfTRW5ITVJ?
NCI-H1792NXn5VFdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrxfFJpUUN3ME20PU45PTF6IN88US=>Mk\PV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]
Features A selective inhibitor of native and mutant Bcr-Abl.

Protocol(Only for Reference)

Cell Assay: [4]

Cell lines Human primary Schwann and schwannoma cells
Concentrations 1-10 μM
Incubation Time 72 hours
Method Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.

Animal Study: [6]

Animal Models Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
Formulation 10% NMP-90% PEG300, PEG300
Dosages 75 mg/kg, 100 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Weisberg E, et al. Blood. 2007, 109(5), 2112-2120.

[2] Liu Y, et al. J Hepatol. 2011, 55(3), 612-625.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto February 2016 Phase 4
NCT02611492 Not yet recruiting Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Assistance Publique - Hôpitaux de Paris December 2015 Phase 3
NCT02627677 Recruiting Chronic Phase Chronic Myeloid Leukemia Ariad Pharmaceuticals December 2015 Phase 3
NCT02546674 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis October 2015 Phase 4
NCT02115386 Not yet recruiting Philadelphia Positive (Ph+) Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis June 2015 Phase 3

view more

Chemical Information

Download Nilotinib (AMN-107) SDF
Molecular Weight (MW) 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 27 mg/mL (50.98 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO/30% PEG 300/5% Tween 80/ddH2O 3mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Customer Product Validation (5)


Click to enlarge
Rating
Source FASEB J 2011 25, 3661-3673. Nilotinib (AMN-107) purchased from Selleck
Method Analyzing cell apoptosis
Cell Lines Ba/F3-p210T315I cells
Concentrations 0-5 μM
Incubation Time 24 h
Results In a parallel study using imatinib/PDMP or nilotinib/PDMP combinations, to our surprise, similar significant synergy in Ba/F3-p210T315I cells was observed.

Click to enlarge
Rating
Source Molecules 2014 19, 3356-75. Nilotinib (AMN-107) purchased from Selleck
Method Western blot
Cell Lines K562, CD34+CD38- cells
Concentrations 0, 0.01, 0.1, 1 uM
Incubation Time 12 h
Results Since nilotinib targets the Bcr-Abl kinase in CML cells, we evaluated its ability to inhibit kinase activity in ABCB1- and ABCG2-overexpressing CD34+CD38- cells. In K562 cells, nilotinib effectively inhibited the phosphorylation of Bcr-Abl and CrkL (a surrogate marker of Bcr-Abl activity) at a concentration of 0.1 umol/L. However, in CD34+CD38- cells, nilotinib failed to completely inhibit the phosphorylation of Bcr-Abl and CrkL even when cells were exposed to concentration up to 1.0 umol/L.

Click to enlarge
Rating
Source Leukemia Res 2012 36, 1311-1314. Nilotinib (AMN-107) purchased from Selleck
Method Thymidine uptake Uptake assay
Cell Lines K562, MEG-01 cells
Concentrations 0.1-10uM
Incubation Time 20 min
Results Nilotinib was much more potent than imatinib to inhibit nucleoside transport. It prevented the uptake of thymidine in K562 cells by 97% at 10 uM, a level that was similar to the one obtained with the vasodilatator molecule dipyridamole. Nilotinib was also very efficient at 1 and 0.1 uM; it blocked the entry of thymidine by 90 and 74%, respectively (Fig. 2a). With the MEG-01 cell line, nilotinib was also extremely potent and blocked the entry of thymidine by 96, 92 and 60% with 10, 1 and 0.1 uM nilotinib, respectively (Fig. 2b).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunoblot analyses
Cell Lines LNCaP, PC-3, DU-145 cells
Concentrations 10 uM
Incubation Time 24 h
Results It shows a robust overexpression of phospho-ERK1/2 T202/Y204 in nilotinib-treated DU-145 cells (B). An up-regulation of phospho-ERK1/2 T202/Y204 was also detectable in nilotinib-treated LNCaP cells, albeit at a lower level, and was not found in PC-3 cells (C).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Xenografted DU-145 cells
Concentrations 5 mg/kg/d
Incubation Time 21 days
Results Accoding to published animals experiments, DU-145 xenografts from a representative experiment in which nilotinib was used at a 75-mg/kg/d concentration. It's found a significant increase of phospho-ERK-positive residual tumor cells from a mean of 67.5 cells per high-powerfield in controls to 131.1 cells per high-powerfield in DU-145 xenografts treated for 21 days with nilotinib (P< 0.0005).

Product Use Citation (18)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcr-Abl Products

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

  • Bafetinib (INNO-406)

    Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

    Features:Dual Bcr-Abl/Lyn inhibitor.

  • Degrasyn (WP1130)

    Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

    Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.

  • DCC-2036 (Rebastinib)

    DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

    Features:A conformational control inhibitor of Abl1 and T315I Abl1.

  • GZD824 Dimesylate

    GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

  • GNF-2

    GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Recently Viewed Items

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107) price | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) solubility dmso | Nilotinib (AMN-107) purchase | Nilotinib (AMN-107) manufacturer | Nilotinib (AMN-107) research buy | Nilotinib (AMN-107) order | Nilotinib (AMN-107) mouse | Nilotinib (AMN-107) chemical structure | Nilotinib (AMN-107) mw | Nilotinib (AMN-107) molecular weight | Nilotinib (AMN-107) datasheet | Nilotinib (AMN-107) supplier | Nilotinib (AMN-107) in vitro | Nilotinib (AMN-107) cell line | Nilotinib (AMN-107) concentration | Nilotinib (AMN-107) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us